DanCann Pharma A/S was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas.
1. Where are you right now and what do the next few years look like?
Currently we are in the process of building up the entire business - including all the different departments. Remarkable is our import and distribution department, which we expect to have approved in Q1 2021 by the Danish Medicines Agency - and including first products. In parallel, several facilities are being built - including the production of raw materials (APIs) and the manufacture of end-user pharmaceuticals.
2. What does your vision look like?
DanCann Pharma is built from a foundation of care, we grow with a passion and vision to improve health and life quality for patients with challenges. We challenge status quo, based on knowledge and innovation and we innovate life-changing technology – and if that means we need to challenge conventions, then that is what we do.
3. What are your biggest challenges?
The biggest challenges are clearly the navigation in the regulatory field, which is very complex from nation to nation, in some cases all the way down from state to state.
There is also a huge amount of work on acceptance and reducing stigma - although something that is in a strong and positive progress.
Lastly, there is an enormous amount of work involved in taking care of the doctors and training them - as this new industry around medical cannabis is completely new to everyone - even the doctors.
4. What has, in the near future, affected / affects the company's position the most?
The fact that medical cannabis continues to impress in two key areas at the moment: strong growth rate and rising popularity- and acceptance – an extremely powerful combination for industry-related companies among the first movers in Europe.
We look forward to another great year for the industry in 2021, perhaps maybe the best ever in terms of legalization and investment opportunities.
5. What can a shareholder expect from you as a company? Why DanCann Pharma?
I would start by saying something as cheeky as due to our common sense and approach to the business - compared to many other players in the industry that we would call an irresponsible cash burn for their investors and no particular understanding of the essence of the business and the landscape they act in.
In addition, our approach to pharma - and the more IP-based platform than ”just” producing raw materials and huge volumes - what we assume will be no brainer products (classic formulations of oils, etc.) which will be one big competition to the death once the industry is established - we compare it a bit with the market for generics (generic drugs) - where the top five players take the market – and the rest dies. We cannot protect isolated active substances alone, as this is everyone's property so to speak.
We especially see the value further out in the value chain around differentiated formulations and associated innovative delivery systems built on a more IP based platform and thereby the unique and protected position among our competitors and colleagues.
Personally, I also think that we appear to be an extremely attractive case at the moment and has received an immediately harsh reception in the market for no particular reason (simply speculation) - also compared to other competitors without mentioning names - so you’ll have to do the homework yourself from here. 😉
We have a solid cash - we have implemented some strong initiatives - we have raised more than +55 MDKK in 2020 and currently have a market cap which fluctuates around 65 MDKK (the trend right now) as of today's date (28 December 2020) and an extremely interesting calendar in terms of trickers in the new year 2021.
If you believe in the medical cannabis industry and the huge growth potential that awaits the industry, I think your money is well placed in our company.
Aktuellt
SENASTE
